Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...

New data link a common C3 gene variant to higher risk of chronic lung allograft dysfunction and antibody mediated rejection ...

SAN DIEGO -- Kidney transplant patients who shifted into newly recognized microvascular inflammation categories under revised definitions had an intermediate risk of poor allograft outcomes, a large ...

Monitoring donor-derived cell-free DNA is a noninvasive means of detecting antibody-mediated rejection of a transplanted kidney. Monitoring donor-derived cell-free DNA (dd-cfDNA) in kidney transplant ...

Antibody-mediated rejection (AMR) is a critical barrier to long-term allograft survival in organ transplantation. This complex immunological phenomenon occurs when recipient-derived antibodies, ...

The first study, by Everly and colleagues, was a retrospective single-center analysis of 52 kidney transplant recipients with biopsy-proven acute rejection diagnosed between January 1, 2003, and ...

After lung transplantation, infection with Pseudomonas aeruginosa independently predicted antibody-mediated rejection (AMR), researchers found. Through a series of mouse-model studies, the researchers ...

Transplantation of organs or tissues between genetically nonidentical individuals of the same species (and different species) is plagued by rejection and its associated problems. "Foreignness" is ...

Biogen (NASDAQ:BIIB) has received U.S. FDA breakthrough therapy designation for felzartamab, its candidate being developed to treat antibody-mediated rejection of kidney transplants. Felzartamab is an ...

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure Second SHORE Study ...